Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

Related Articles by Review for PubMed (Select 23329590)

1.

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.

Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, Mowatt G, Vale L.

Pharmacoeconomics. 2013 Jan;31(1):15-24. doi: 10.1007/s40273-012-0006-5. Review.

PMID:
23329590
2.

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.

Rafia R, Simpson E, Stevenson M, Papaioannou D.

Pharmacoeconomics. 2013 Jun;31(6):471-8. doi: 10.1007/s40273-013-0044-7. Review.

PMID:
23568332
3.

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.

Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M.

Pharmacoeconomics. 2010;28(5):351-62. doi: 10.2165/11532160-000000000-00000. Review.

PMID:
20131924
4.

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

Whyte S, Pandor A, Stevenson M.

Pharmacoeconomics. 2012 Dec 1;30(12):1119-32. doi: 10.2165/11597210-000000000-00000. Review.

PMID:
23058097
5.

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.

Boyers D, Jia X, Jenkinson D, Mowatt G.

Pharmacoeconomics. 2012 Jun 1;30(6):483-95. doi: 10.2165/11591550-000000000-00000. Review.

PMID:
22480381
6.

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

Scotland G, Waugh N, Royle P, McNamee P, Henderson R, Hollick R.

Pharmacoeconomics. 2011 Nov;29(11):951-61. doi: 10.2165/11589310-000000000-00000. Review.

PMID:
21854080
7.

Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.

McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, Woolacott N, Palmer S.

Pharmacoeconomics. 2012 Jan;30(1):35-46. doi: 10.2165/11594280-000000000-00000. Review.

PMID:
22136303
8.

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.

Pharmacoeconomics. 2012 Apr;30(4):257-70. doi: 10.2165/11595920-000000000-00000. Review.

PMID:
22283690
9.

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C, Dickson R, Dundar Y, Proudlove C, Shaw R.

Pharmacoeconomics. 2010;28(6):439-48. doi: 10.2165/11532220-000000000-00000. Review.

PMID:
20465313
10.

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.

Health Technol Assess. 2010 Oct;14(Suppl. 2):33-9. doi: 10.3310/hta14suppl2/05. Review.

11.

Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.

Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, Marshall E, Plummer R, Proudlove C.

Pharmacoeconomics. 2013 Dec;31(12):1121-9. doi: 10.1007/s40273-013-0094-x. Review.

PMID:
24114739
12.

Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.

Armstrong N, Joore M, van Asselt T, Misso K, Manning N, Tomini F, Kleijnen J, Riemsma R.

Pharmacoeconomics. 2013 May;31(5):415-25. doi: 10.1007/s40273-013-0049-2. Review.

PMID:
23580355
13.

Sorafenib for the treatment of advanced hepatocellular carcinoma.

Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D.

Health Technol Assess. 2010 May;14 Suppl 1:17-21. doi: 10.3310/hta14Suppl1/03. Review.

14.

Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.

Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, Woolacott N, Palmer S.

Pharmacoeconomics. 2013 Jul;31(7):551-62. doi: 10.1007/s40273-013-0051-8. Review.

PMID:
23620211
15.

Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.

Craig D, Rice S, Paton F, Fox D, Woolacott N.

Pharmacoeconomics. 2013 Feb;31(2):101-10. doi: 10.1007/s40273-012-0018-1. Review.

PMID:
23341194
16.

The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.

Main C, Pitt M, Moxham T, Stein K.

Health Technol Assess. 2010 Oct;14(Suppl. 2):27-32. doi: 10.3310/hta14suppl2/04. Review.

17.

Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.

Wade R, Rose M, Neilson AR, Stirk L, Rodriguez-Lopez R, Bowen D, Craig D, Woolacott N.

Pharmacoeconomics. 2013 Oct;31(10):841-52. doi: 10.1007/s40273-013-0083-0. Review.

PMID:
23996108
18.

Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.

Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, Dickson R, Ramani VS, Proudlove C.

Health Technol Assess. 2010 Oct;14(Suppl. 2):71-9. doi: 10.3310/hta14suppl2/10. Review.

19.

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.

Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, Dickson R, Tudur Smith C, Davis H, Green J, Pearson M.

Health Technol Assess. 2010 May;14 Suppl 1:47-53. doi: 10.3310/hta14Suppl1/07. Review.

20.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk